NCT06470061 · Phase 2 · NOT YET RECRUITING
RQC for the Prevention of Alzheimer's Disease and Retinal Amyloid-β
This trial tests whether a daily mix of three plant compounds, resveratrol, quercetin, and curcumin (RQC), taken for 24 months can slow amyloid buildup in the retina and protect thinking skills in people 50 to 90 with very early Alzheimer's changes. It is a Phase 2 trial: testing whether it works and is safe, not yet proven or approved.
You may qualify if
- 50-90 years of age at screening.
- Male or female
- Any race or ethnicity.
- Provide written informed consent.
- Availability for the duration of the study.
- Ability to speak, read, and understand English.
- Ability to take oral medication and be willing to adhere to the RQC regimen.
- Have adequate literacy, vision, and hearing for neuropsychological testing at screening
You're excluded if
- MMSE score 0-25, indicating more than subtle cognitive abnormalities
- CDR-SB score > 0, indicating functional impairment
- Clinical diagnosis of any non-Alzheimer's disease (AD) type of mild cognitive impairment (MCI) or dementia
- Taking pharmaceutical anti-Aβ monoclonal antibodies (i.e., Leqembi, Aduhelm).
- Participation in another clinical study with an investigational product during the last 90 days.
- Presence of hepatic disease or kidney disease
- Clinically significant or unstable hematologic, cardiovascular, pulmonary, gastrointestinal, endocrine metabolic, or other systemic disease.
- Diagnosis of gastrointestinal or stomach condition including but not limited to irritable bowel syndrome (IBS), ulcerative colitis, peptic ulcers, Crohn's disease, gastroesophageal reflux disease, gastritis, severe dyspepsia, and intestinal malabsorption.
- Clinically significant abnormal values in hematology, coagulation and platelet function, clinical chemistry, or urinalysis at screening (such as those with prolonged prothrombin time (PT), anemia, low neutrophil or platelet count, elevated liver function tests, low glomerular filtration rate).
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2024-06-26